北美临床试验管线追踪-Clinical Trial Pipeline Tracker

Summary of Clinical Trial Pipeline Tracker Industry Overview - Industry: Biopharma - Region: North America - Industry View: In-Line for Biotechnology, Attractive for North America [6][6] Key Changes in Clinical Trials New Trials Initiated 1. Acadia: Initiated a Phase 3 trial (NCT07095465) of ACP-204 for Lewy Body Dementia Psychosis [8] 2. BeOne Medicines: Initiated a Phase 2 trial (NCT07100938) for BGB-45035 versus placebo in adults with moderate to severe active rheumatoid arthritis [8] 3. Bristol-Myers Squibb: - Initiated a Phase 2/3 trial (NCT07100080) of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapy [8] - Initiated a Phase 1 trial (NCT07105059) of Teclistamab and Mezigdomide in people with multiple myeloma [8] 4. Jazz Pharmaceuticals: Initiated a Phase 2 trial (NCT07102381) of Zanidatamab in combination with chemotherapy for HER2-positive breast cancer [8] 5. Neurocrine: Initiated a Phase 3 trial (NCT07105098) for NBI-1117568 in inpatient adults with schizophrenia [8] Trials Currently Recruiting 1. Abbvie: Recruiting in a Phase 2 study (NCT07023289) to assess adverse events in adults receiving Telisotuzumab Adizutecan for colorectal cancer [9] 2. Biohaven: Recruiting in a Phase 1 study (NCT07054684) of BHV-1400 in IgA nephropathy [9] 3. Bristol-Myers Squibb: - Recruiting in a Phase 2 study (NCT06762769) of Isatuximab and Iberdomide for high-risk smouldering myeloma [9] - Recruiting in multiple other studies for various conditions [9][17] Suspended Trials - No specific trials were reported as suspended during this period [3][19] Terminated Trials - No specific trials were reported as terminated during this period [4][21] Other Important Information - The report includes a comprehensive list of trials, their stages, and identifiers for tracking purposes [18][22] - The document emphasizes the potential conflicts of interest due to Morgan Stanley's business relationships with the companies covered [6][6] Conclusion The biopharma industry in North America is actively progressing with numerous new clinical trials, particularly in oncology and neurodegenerative diseases. The ongoing recruitment efforts indicate a robust pipeline, while the industry outlook remains positive.